Roivant has its own TYK2/JAK1 inhibitor in development in the form of brepocitinib, which the biopharma licensed from Pfizer ...

Recent findings regarding interferon and Janus kinase inhibition may hold clues to improving outcomes in patients with ...

The story of chronic itch and its impact on quality of life is one dermatologists have heard often. Until recently, treatment ...

Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...